

# Elena N Parovichnikova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/563484/publications.pdf>

Version: 2024-02-01

79  
papers

475  
citations

933264

10  
h-index

752573

20  
g-index

97  
all docs

97  
docs citations

97  
times ranked

815  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Diseaseâ€”A Phase II Study. <i>Stem Cells International</i> , 2012, 2012, 1-8.	1.2	98
2	Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. <i>Experimental Hematology</i> , 2003, 31, 1301-1309.	0.2	81
3	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. <i>Hematology</i> , 2019, 24, 337-348.	0.7	48
4	The Results of the Russian Clinical Trial of Mesenchymal Stromal Cells (MSCs) in Severe Neutropenic Patients (pts) with Septic Shock (SS) (RUMCESS trial). <i>Blood</i> , 2015, 126, 2220-2220.	0.6	28
5	Analysis of results of acute graft-versus-host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. <i>Biochemistry (Moscow)</i> , 2014, 79, 1363-1370.	0.7	22
6	Blinatumomab vs historic standardâ€”ofâ€”care treatment for minimal residual disease in adults with Bâ€”cell precursor acute lymphoblastic leukaemia. <i>European Journal of Haematology</i> , 2020, 104, 299-309.	1.1	17
7	The CD68 protein as a potential target for leukaemia-reactive CTL. <i>Leukemia</i> , 2002, 16, 2019-2026.	3.3	14
8	Analysis of multipotent mesenchymal stromal cells used for acute graftâ€”versusâ€”host disease prophylaxis. <i>European Journal of Haematology</i> , 2016, 96, 425-434.	1.1	11
9	Alterations of the bone marrow stromal microenvironment in adult patients with acute myeloid and lymphoblastic leukemias before and after allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 408-417.	0.6	11
10	Changing the Properties of Multipotent Mesenchymal Stromal Cells by IFNÎ³ Administration. <i>Bulletin of Experimental Biology and Medicine</i> , 2017, 163, 230-234.	0.3	11
11	Effect of priming of multipotent mesenchymal stromal cells with interferon Î³ on their immunomodulating properties. <i>Biochemistry (Moscow)</i> , 2017, 82, 1158-1168.	0.7	9
12	Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells. <i>Stem Cells International</i> , 2018, 2018, 1-7.	1.2	9
13	Incidence, etiology, risk factors, and outcomes of preâ€”engraftment bloodstream infections after first and second allogeneic hematopoietic cell transplantation. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	9
14	The ability of multipotent mesenchymal stromal cells from the bone marrow of patients with leukemia to maintain normal hematopoietic progenitor cells. <i>European Journal of Haematology</i> , 2016, 97, 245-252.	1.1	8
15	Recombinant MHC tetramers for isolation of virus-specific CD8+ cells from healthy donors: Potential approach for cell therapy of posttransplant cytomegalovirus infection. <i>Biochemistry (Moscow)</i> , 2016, 81, 1371-1383.	0.7	8
16	Level of Granzyme B-positive T-regulatory cells is a strong predictor biomarker of acute Graft-versus-host disease after day +30 after allo-HSCT. <i>Leukemia Research</i> , 2017, 54, 25-29.	0.4	7
17	Myelodysplastic syndromes with isolated deletion of the long arm of the chromosome X as a sole cytogenetic change. <i>Cancer Genetics and Cytogenetics</i> , 2006, 167, 47-50.	1.0	5
18	Pharmacokinetics of Doxorubicin in Patients with Lymphoproliferative Disorders after Infusion of Doxorubicin-Loaded Erythrocytes. , 1997, , 137-142.		5

#	ARTICLE	IF	CITATIONS
19	Blinatumomab + Tyrosine Kinase Inhibitors in the Treatment of Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Patients - Clinical Efficacy and Peripheral Blood Lymphocytes Subpopulations Kinetics. <i>Blood</i> , 2016, 128, 4024-4024.	0.6	5
20	Immunophenotypic characteristics of multipotent mesenchymal stromal cells that affect the efficacy of their use in the prevention of acute graft vs host disease. <i>World Journal of Stem Cells</i> , 2020, 12, 1377-1395.	1.3	5
21	Adhesion capacity and integrin expression by dendritic-like cells generated from acute myeloid leukemia blasts by calcium ionophore treatment. <i>Experimental Hematology</i> , 2004, 32, 563-570.	0.2	3
22	Long-term survival of donor bone marrow multipotent mesenchymal stromal cells implanted into the periosteum of patients with allogeneic graft failure. <i>International Journal of Hematology</i> , 2016, 104, 403-407.	0.7	3
23	The outcome of Ph-negative acute lymphoblastic leukemia presenting during pregnancy and treated on the Russian prospective multicenter trial RALL-2009. <i>Leukemia Research</i> , 2021, 104, 106536.	0.4	3
24	Haploidentical Stem Cell Transplantation with TCR Alpha/Beta and CD19 Depletion in Adult Patients with Hematological Malignancies. <i>Blood</i> , 2019, 134, 5648-5648.	0.6	3
25	The Secretion of Paraprotein Is Associated with Bone Marrow Involvement in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 2646-2646.	0.6	3
26	Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 778-784.	0.2	2
27	Non-Intensive but Constant and Exhausting Action on the Leukemic Clone Is a Reasonable and Effective Treatment Approach in Adult Acute Lymphoblastic Leukemia: Results of the Russian Acute Lymphoblastic Leukemia (RALL) Study Group. <i>Blood</i> , 2014, 124, 3662-3662.	0.6	2
28	Alterations in multipotent mesenchymal stromal cells properties: in vitro model of their interactions with allogeneic lymphocytes. <i>Cellular Therapy and Transplantation</i> , 2016, 5, 39-41.	0.2	2
29	High expression of granzyme B in conventional CD4+ T cells is associated with increased relapses after allogeneic stem cells transplantation in patients with hematological malignancies. <i>Transplant Immunology</i> , 2021, 65, 101295.	0.6	1
30	Comparison of polymerase chain reaction and flow cytometry for measuring telomere length of human leukocytes. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2021, 66, 154-159.	0.2	1
31	Extracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 811-817.	0.2	1
32	Addition of ATRA to the Maintenance Protocol Did Not Improve Disease-Free Survival: Results of the Russian APL Trial.. <i>Blood</i> , 2007, 110, 4374-4374.	0.6	1
33	Characteristics of Mesenchymal Multipotent Stromal Cells Determine Their Effectiveness for Acute Graft Versus Host Disease Prophylaxis after Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 2014, 124, 2484-2484.	0.6	1
34	Absence of High-Dose Consolidation Courses and Low Numbers of Allogeneic HSCTs Did Not Affect Overall Optimistic Results in B-Cell Precursor Ph-Negative Adult ALL Patients Treated By Non-Intensive but Non-Interruptive ALL-2009 Protocol: Data of the Russian ALL Study Group. <i>Blood</i> , 2015, 126, 2497-2497.	0.6	1
35	Post-Transplant Cyclophosphamide Spares Granzyme B Expression in T Regulatory Cells (Treg), but Not in CD8+ T and NK Cells after Allogeneic HSCT. <i>Blood</i> , 2015, 126, 5422-5422.	0.6	1
36	Alterations of the Bone Marrow Stromal Microenvironment in Adult Patients with Leukemia before and after the Treatment. <i>Blood</i> , 2016, 128, 2668-2668.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Analysis of Expression of Genes Involved in Immune Response Modulation in Silent Multipotent Mesenchymal Stromal Cells. <i>Bulletin of Experimental Biology and Medicine</i> , 2012, 153, 244-248.	0.3	0
38	Co-Culturing of Multipotent Mesenchymal Stromal Cells with Autological and Allogenic Lymphocytes. <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 164, 446-452.	0.3	0
39	Optimal Dose Horse Antithymocyte Globulin for the Treatment of Adult Patients with Aplastic Anemia: A Prospective Randomized Comparative Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S298.	0.2	0
40	Long-Term Results of Russian Prospective Multicenter Trial of the Addition R-HMA to R-DA-EPOCH in Patients with Untreated High-Grade Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S280-S281.	0.2	0
41	Can Immune Synapse Parameters Determine Lymphoma Type?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S301.	0.2	0
42	The Type of BCR/ABL1 Fusion Transcript Does Not Affect Therapy Effectiveness of Ph-Positive Acute Lymphocytic Leukemia in the Era of Tyrosine Kinase Inhibitors in Russian Trial Ph+ALL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S186-S187.	0.2	0
43	Alterations in multipotent mesenchymal stromal cells from the bone marrow of acute myeloid leukemia patients at diagnosis and during treatment. <i>Leukemia and Lymphoma</i> , 2019, 60, 2042-2049.	0.6	0
44	Liã€“Fraumeni syndrome in adult patients with acute lymphoblastic leukemia. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 763-769.	0.2	0
45	Development of program therapy for patients with acute myeloid leukemia under the age of 60 years, based on the principles of differentiated effects. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 753-762.	0.2	0
46	Repeated haploidentical allogeneic hematopoietic stem cell transplantation with TCR Î±Î²/CD19 depletion in patient with primary myelofibrosis. Case report. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 805-810.	0.2	0
47	A case report of familial dyskeratosis congenital. Case report. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 818-825.	0.2	0
48	Multiple primary tumor of hematopoietic tissue: myeloid sarcoma in combination with mantle cell lymphoma. Case report. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 793-799.	0.2	0
49	Deficient IL-10 Secretion by Dendritic Cells (DCs) and Activated Lymphocytes in Aplastic Anemia (AA) Patients.. <i>Blood</i> , 2004, 104, 3843-3843.	0.6	0
50	Hematopoietic Chimerism in Patients with Hematological Malignancies Treated with Donor Lymphocyte Infusions Combined with IL-2 for Relapse after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 5025-5025.	0.6	0
51	Splenectomy In Patients with MDS. <i>Blood</i> , 2010, 116, 1879-1879.	0.6	0
52	Cytogenetic Characteristic of Mesenchymal and Hematopoetic Progenitor Cells in Myelodysplastic Syndromes and Acute Myeloid Leukemias with Myelodysplasia-Related Changes. <i>Blood</i> , 2012, 120, 4899-4899.	0.6	0
53	Plasmapheresis Is an Effective Approach Preventing Clinically Significant Tumor Lysis Syndrome during Induction Therapy in AML Patients with Hyperleukocytosis. <i>Blood</i> , 2014, 124, 5268-5268.	0.6	0
54	Detection of B-Cell Clonality in Bone Marrow Is Independent Predictor of Outcome in De Novo Diffuse Large B-Cell Lymphoma Patients Treated with High-Dose Chemotherapy. <i>Blood</i> , 2014, 124, 2967-2967.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Conventional 7+3 Consolidation Is Equal in Long-Term Outcome to High Dose ARA-C in Case of the High Total Doses of Different Anthracyclines/Anthracenedione in Induction/Consolidation - the Interim Results of Russian Randomized Multicenter AML-10 Trial. <i>Blood</i> , 2014, 124, 3667-3667.	0.6	0
56	Low Density Granulocytes in Patients after Allogeneic Hematopoietic Stem Cells Transplantation (allo-HSCT): A Distinct Class of Neutrophils in Systemic Alloimmunity. <i>Blood</i> , 2015, 126, 4614-4614.	0.6	0
57	Successful Experience of Treatment of Angioimmunoblastic T-Cell Lymphoma By Prolonged Therapy. <i>Blood</i> , 2015, 126, 5063-5063.	0.6	0
58	Correlation Between c-MYC Gene Expression and Response after Induction Therapy Among Patients with Newly Diagnosed Multiple Myeloma and Monoclonal Gammopathy Undetermined Significance. <i>Blood</i> , 2015, 126, 5324-5324.	0.6	0
59	Influence of KIR Genes and HLA Class I Ligands on Overall and Event-Free Survivals after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia. <i>Blood</i> , 2015, 126, 5509-5509.	0.6	0
60	Alterations in the Physiology of Multipotent Mesenchymal Stromal Cells from the Bone Marrow of Patients with Leukemia. <i>Blood</i> , 2015, 126, 4768-4768.	0.6	0
61	Addition of R-HMA to R-DA-EPOCH Favourably Changes the Outcome in Patients with Untreated High-Grade Diffuse Large B-Cell Lymphoma: The First Results of Russian Prospective Multicenter Trial. <i>Blood</i> , 2015, 126, 2708-2708.	0.6	0
62	Multiple Clonal TCR Gene Rearrangements Are Typical in Peripheral T-Cell Lymphoma Not Otherwise Specified. <i>Blood</i> , 2015, 126, 5036-5036.	0.6	0
63	Late Clonal Disorders in Patients with Aplastic Anemia. <i>Blood</i> , 2015, 126, 4787-4787.	0.6	0
64	Long-Term Efficacy of the Combined Immunosuppressive Therapy (IST): Cyclosporine with/without Splenectomy - in Patients with Different Forms of Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 5238-5238.	0.6	0
65	Actual Status of Inhibitor Hemophilia Management in Russia. <i>Blood</i> , 2015, 126, 5579-5579.	0.6	0
66	Granzyme B expression in T-regulatory cells is a strong predictor of acute graft-versus-host disease after day +30 in patients with classic immunosuppression after allo-HSCT. <i>Cellular Therapy and Transplantation</i> , 2016, 5, 22-25.	0.2	0
67	Usage of online platforms for remote evaluation of the quality of life in patients following allogeneic transplantation of hematopoietic stem cells on the territory of Russian Federation and ex-USSR. <i>Cellular Therapy and Transplantation</i> , 2016, 5, 30-33.	0.2	0
68	Functional disparity of graft-derived T lymphocytes: experimental data. <i>Cellular Therapy and Transplantation</i> , 2016, 5, 26-29.	0.2	0
69	Treatment of refractory intestinal acute GvHD using multipotent mesenchymal stromal cells (MMSC). <i>Cellular Therapy and Transplantation</i> , 2016, 5, 34-36.	0.2	0
70	The Different Treatment Approaches in Younger Patients with Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 5345-5345.	0.6	0
71	No Differences in the Treatment Outcome in T-Cell Acute Lymphoblastic Leukemia/Lymphoma Regarding the Initial Bone Marrow Blasts Count: Results of the Russian Acute Lymphoblastic Leukemia (RALL) Study Group. <i>Blood</i> , 2016, 128, 5149-5149.	0.6	0
72	Granzyme B Expression in T-Regulatory Cells Is a Strong Predictor of Acute Graft-Versus-Host Disease after Day +30 in Patients with "Classic" Immunosuppression after Allo-HSCT. <i>Blood</i> , 2016, 128, 2238-2238.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Pregnancy Is a Poor Prognostic Factor for AML Outcome. <i>Blood</i> , 2016, 128, 5171-5171.	0.6	0
74	Modification of Gene Expression in Mesenchymal Stromal Cells of the Leukemia Patients during Chemotherapy. <i>Blood</i> , 2016, 128, 5065-5065.	0.6	0
75	De-Intensification of the Chemotherapy Did Not Affect the Outcome of Ph-Positive Acute Lymphocytic Leukemia Patients in the Era of Tyrosine Kinase Inhibitors. <i>Blood</i> , 2016, 128, 2805-2805.	0.6	0
76	Immune Privileged Features of Multipotent Mesenchymal Stromal Cells Are Lost after Co-Cultivation with Allogeneic Lymphocytes in Vitro. <i>Blood</i> , 2016, 128, 5722-5722.	0.6	0
77	Substantial Variation in Nlv-Specific T Cells Phenotype and Activation Ability upon Antigen Stimulation May Have Implications for Virus-Specific Adoptive Therapy. <i>Blood</i> , 2016, 128, 5725-5725.	0.6	0
78	Treatment of Primary Aggressive Gastrointestinal Lymphomas with Intensive Chemotherapy: A 14-Year Experience. <i>Blood</i> , 2016, 128, 5388-5388.	0.6	0
79	Outcomes of Pregnant Women with Acute Leukemia Treated for Life-Threatening Complications. <i>Blood</i> , 2016, 128, 5976-5976.	0.6	0